Cytodyn Inc at CytoDyn (OTC: CYDY) Coronaovirus Treatment gets FDA EMERGENCY IND + update on HIV & Cancer pipeline Transcript
Okay. Good afternoon, everybody, and welcome to Wall Street Reporter's Next Super Stock livestream for today, March 19, 2020. I'm very proud to be bringing you two great companies which many of you have been following since they first presented at our livestream conferences back in August, that's CytoDyn and Nextech. Both of these stocks have skyrocketed for over 300% since they first presented their story to our audience. And of course, the market has had some turbulence.
Both of these stocks have gotten knocked around a little bit. But the key point is this: the CEOs of both CytoDyn and Nextech, they've been here, they've been in front of investors, engaging with investors and shareholders from the beginning when the stocks were cheap, when the stocks moved up, when the stocks came down. And here they are again, which is a key point because a lot of companies, as a lot of microcap investors know -- a lot of companies, they hide when the markets turn. So really, this is the mark of true leadership that the CEOs are here with you today in these crazy times
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
